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ABSTRACT: Cigarette smoking, one of the most pervasive habits in society, presents many 
well established health risks. While lung cancer is probably the most common and well 
documented disease associated with tobacco exposure, it is becoming clear from recent re-
search that many other diseases are causally related to smoking. Whether from direct smok-
ing or inhaling environmental tobacco smoke (ETS), termed secondhand smoke, the cells of 
the respiratory tissues and the lining pulmonary surfactant are the first body tissues to be 
directly exposed to the many thousands of toxic chemicals in tobacco. Considering the vast 
surface area of the lung and the extreme attenuation of the blood-air barrier, it is not surpris-
ing that this organ is the primary route for exposure, not just to smoke but to most environ-
mental contaminants. Recent research has shown that the pulmonary surfactant, a complex 
mixture of phospholipids and proteins, is the first site of defense against particulates or gas 
components of smoke. However, it is not clear what effect smoke has on the surfactant. 
Most studies have demonstrated that smoking reduces bronchoalveolar lavage phospholipid 
levels. Some components of smoke also appear to have a direct detergent-like effect on the 
surfactant while others appear to alter cycling or secretion. Ultimately these effects are re-
flected in changes in the dynamics of the surfactant system and, clinically in changes in lung 
mechanics. Similarly, exposure of the developing fetal lung through maternal smoking re-
sults in postnatal alterations in lung mechanics and higher incidents of wheezing and cough-
ing. Direct exposure of developing lung to nicotine induces changes suggestive of fetal 
stress. Furthermore, identification of nicotinic receptors in fetal lung airways and corre-
sponding increases in airway connective tissue support a possible involvement of nicotine in 
postnatal asthma development. Finally, at the level of the alveoli of the lung, colocalization 
of nicotinic receptors and surfactant-specific protein in alveolar cells is suggestive of a role 
in surfactant metabolism. Further research is needed to determine the mechanistic effects of 
smoke and its components on surfactant function and, importantly, the effects of smoke 
components on the developing pulmonary system. 
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INTRODUCTION 
Tobacco in various forms, as well as tobacco-
related compounds such as marijuana, represent agents 
that present serious and insidious health risks to the 
general population. Both of these drugs have long and 
interesting histories. As this review is focused primarily 
on tobacco, marijuana use will be discussed only as it 
reflects on health effects resulting from both tobacco 
and marijuana. Tobacco use passed into Europe in the 
late sixteenth century after initial encounters between 
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Tobacco was seen often as a medicine. Several well 
known European physicians extolled the virtues of to-
bacco as a medicinal herb [1] and tobacco enemas were 
recommended for treatment of cholera and to loosen the 
bowels [2]. Ironically, one of among some twenty ail-
ments purportedly amenable to tobacco was cancer [2]. 
For the next two centuries modest changes in cultiva-
tion, largely in the American colonies, provided in-
creasing supplies of tobacco to Europe although it 
should be noted that consumption was taken largely in 
the form of chewing plugs [2], snuffed, or smoked in 
pipes [3]. It was not until the late 1860’s that a sudden 
change in consumption occurred. In fact the change was 
startling. According to Tilley [4], in 1869 about 2 mil-
lion cigarettes were being manufactured in the United 
States and it was uncommon to see someone smoking 
in public. Some ten years later with the advent of new 
curing methodologies, the introduction of the Bonsack 
cigarette-making machine, and as the cigarette fashion 
took hold, 300 million units were produced. Indeed, the 
Bonsak machine could produce some 100,000 ciga-
rettes a day, the equivalent of the work of 30-40 labour-
ers. These machines marked an innovative turning point 
for the tobacco industry [5]. The production level initi-
ated by the automated machines was reflected in the 
consumption trend as tobacco sales between the late 
nineteenth century until the end of the first World War 
underwent a major shift as 50% of sales were accounted 
now by cigarettes rather than pipe tobacco [6]. With 
this remarkable shift to cigarettes and the concurrent 
increase in smoke inhalation compared to snuffed or 
chewed tobacco, deaths due to lung cancer showed 
dramatic increases [7]. 
The long history of both tobacco and marijuana 
as addictive drugs, their common routes of exposure, 
and their many common components make for an inter-
esting dilemma in the health care field for both com-
mon and different reasons. On the one hand, the detri-
mental effects of cigarette smoking through both pri-
mary and secondary routes of exposure have become 
clear over the past few years [8]. The list of potential 
health risks is large and continues to grow after pro-
longed years of tobacco exposure. On the other hand, 
there is a general movement toward the legalization and 
use of marijuana, particularly for medicinal purposes. 
Ironically marijuana smoking presents many of the 
same risks as tobacco smoking; this is largely ignored 
in the public press. Surveys of public opinion suggest 
that marijuana use is generally considered relatively 
innocuous. Yet many of the same components that 
make tobacco such a health risk are present in mari-
juana smoke. These components are associated with 
elevated risk of heart disease, ovarian cancer, bone can-
cer, breast cancer, pancreatic cancer, oral cancers, blad-
der cancer, and of course lung cancers. Indeed the sepa-
ration of marijuana-induced health risks from tobacco-
induced risks is difficult, as most users are dependent 
on both drugs as well as potentially other more potent 
drugs. Since the respiratory tree and lungs are the first 
areas of exposure to these agents, the interactions of 
smoke components with the cells, lining fluids and ma-
terials of the lungs are of considerable interest. A great 
deal has been written about potential smoke effects on 
many of the component cells of the conducting and 
respiratory tissues within the lung. While it is clear that 
smoking is by far the greatest risk factor associated 
with development of lung cancer [9, 10], the diversity 
of products in tobacco and marijuana smoke, the large 
number of pulmonary cell types and the complex envi-
ronment of the lung make the delineation of smoke-
induced diseases very difficult. 
 
THE PULMONARY SYSTEM 
The pulmonary system which encompasses not 
only the lungs but the conducting airways, the nasal 
cavities, nasopharynx, oropharynx and larynx, is proba-
bly the most complex system in the body. This is due to 
the fact that the pulmonary system provides the most 
intimate interface with the external environment of any 
region of the body. The surface area of the lung tissue, 
approximately 120m
2 by recent estimates [11, 12, 13], 
represents the largest body surface area exposed to the 
environment. At the level of the alveoli where gas ex-
change occurs, the biological barrier presents as an ex-
tremely attenuated interface composed of the cell mem-
branes and fused basal laminae. At the same time this 
arrangement must provide protection against a vast 
range of biological and non-biological elements. This is 
obviously a difficult undertaking. This complex envi-
ronment must in part account for the large numbers and 
variations of cell types detected in the conducting air-
ways and respiratory tissues [14]. Some 40 different 
cell types have been described in the lining tissues, 
bronchial tree and respiratory tissues [14]. Their func-
tions have only begun to be elucidated and their rela-
tionships to the complex disease processes that affect 
the lungs have only begun to become clear. Within this 
context, recent research has shown that pulmonary sur-
factant is a major player both in terms of the intrinsic 
function of the lungs as well as presenting a first line of 
defense against immunological, biological and non-
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out, every organism or particle that enters the pulmo-
nary system in the inspired air comes into contact with 
the pulmonary surfactant [18]. Thus in addition to its 
surface tension lowering capabilities, surfactant un-
doubtedly plays a number of important roles, such as 
mounting of an immunological defense or activating 
intrinsic cellular responses. 
Before turning to a discussion of the interaction 
of tobacco smoke and related agents with the pulmo-
nary surfactant system, it is important to have a concep-
tual knowledge of exactly what composes the lung sur-
factant. Therefore, we will begin our discussion in the 
form of a short review of what our latest concepts are 
concerning the surfactant, its composition and function. 
It should be noted, however, that this short review is not 
intended to be exhaustive as extensive reviews are 
available by acknowledged experts on pulmonary sur-
factant (see references for a complete issue devoted to 
the pulmonary surfactant [19, 20]). 
 
THE PULMONARY SURFACTANT  
Within the lung, an aqueous lining layer exists to 
varying degrees within the alveoli and intrapulmonary 
duct system [21]. The composition and characteristics 
of this layer are critical to many lung functions, for ex-
ample gas exchange, defense against microorganisms 
and pulmonary compliance. Estimates of the thickness 
and volume of this layer suggest 25mls of total liquid 
for an average 70kgs of body weight resulting in a 
thickness of probably less than 0.1 µm [22]. Within this 
layer the pulmonary surfactant exists and interfaces 
between the alveolar air and lining liquid phases. The 
pulmonary surfactant is an extremely complex mixture 
of components which fall generally into two broad 
categories. The complexity of these components re-
flects the corresponding complex functional role of the 
surfactant and indeed the multifunctional aspects of the 
mix are unique in the body as they reflect the extracel-
lular role as well as the intracellular regulatory aspects 
of the surfactant. The major components of lung surfac-
tant are phospholipids. It has been generally held for 
many years that the surface-active properties of surfac-
tant lie in the domain of these components. However, it 
has become clear over the last decade that such a dis-
tinction is not as clear as it was once held to be, since 
the pulmonary surfactant proteins and their inherent 
characteristics are not simply left over by-products of 
some other system such as the blood vascular system. 
Rather the proteins are both specific and instrumental in 
pulmonary surfactant function. These two characteristic 
components, the phospholipids and proteins, will be 
dealt with individually and their impact on function 
discussed below briefly. 
 
PHOSPHOLIPID COMPONENTS AND THEIR 
CONTRIBUTION TO FUNCTION 
Excellent recent reviews of the biosynthesis, 
composition and functional contributions of the lipid 
components of the pulmonary surfactant are available 
[23, 24] and the reader is referred to these for detailed 
descriptions of the surfactant. The present review will 
provide only a cursory overview as a foundation to 
discussing the effects of smoke inhalation on the sur-
factant. 
The pulmonary surfactant is composed of ap-
proximately 90% lipids [25, 26] with the remainder 
being proteins specifically, and somewhat uniquely, 
associated with functional aspects of the lipids. These 
will be discussed below. The lipid fraction is a complex 
mix of which the majority is phospholipid, accounting 
for about 85% of the total. The remaining fraction, 
composed of neutral lipids, contains some trace 
amounts of triglycerides and fatty acids [27] but its 
main component is cholesterol which may have some 
important functions [28, 29]. Of the phospholipid frac-
tion, phosphatidylcholine accounts for 70-80% of the 
total [30]. While these components are not particularly 
unique in themselves, several features of the surfactant 
are indeed peculiar and of course reflect its specialized 
Figure 1: Arrangement of a molecule of dipalmito-
ylphosphatidylcholine (DPPC) at the interface of the 
air and an aqueous hypophase. The fatty acid moie-
ties are displaced away from the polar water phase 
while the polar head group associates with the wa-
ter. The uniformity of the fatty acid chains allows 
tight packing of adjacent DPPC molecules providing 
a small cross-sectional profile. 
Molecular Cross-section
P almitic acid 
residues
Glycerol backbone
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acid moieties esterified to the glycerol backbone within 
the phosphatidylcholine fraction. Although it may be 
difficult to characterize a certain fatty acid complement 
as being typical given the complexity and huge number 
of possible combinations, biochemical references es-
pouse a general 1-saturated, 2-unsaturated configuration 
for phospholipids arranged on the glycerol backbone at 
least for those components contributing to cell mem-
brane bilayers [31]. However, the pulmonary surfactant 
displays a unique subfraction within the phosphatidyl-
choline fraction. In particular, disaturated phosphatidyl-
choline (DSPC) almost all of which is dipalmitoyl (Fig-
ure 1) accounts for between 60% and 70% of the total 
[20, 32], although it should be noted that some esti-
mates suggest DSPC levels lie more in the 40% range 
[33]. Such discrepancies may be related to maturity, 
species or experimental techniques. This latter possibil-
ity is discussed in detail by Goerke (1998). In fact, re-
cent studies support the contention that species differ-
ences do exist and these may relate to the functional or 
evolutionary background of the surfactant in question. 
For example, the levels of DSPC as a percentage of 
total phospholipid in surfactant show a relative increase 
through vertebrate evolution while the ratio of choles-
terol to total phospholipid seems to decline [34]. Func-
tional changes may also be reflected in surfactant com-
position. In dunnarts, an Australian heterothermic 
marsupial, induction of a state of torpor is associated 
with increases of both the ratios mentioned above [35, 
36]. Similarly lungs of certain air-breathing fish have 
phospholipids that are severalfold less saturated than 
those of reptiles and mammals [37]. Thus, as these au-
thors point out, the presence of high surfactant choles-
terol levels, which may occur rapidly in as little as two 
hours [38], may suggest a protosurfactant which 
evolved as a means of controlling surface viscosity in 
ectothermic animals [28]. 
The defining characteristic of lung surfactant is 
its ability to generate very low surface tension at mini-
mum expansion. Surface tension may be thought of as 
the force that resists expansion of a liquid [36]. This is 
due to the attraction of the molecules for each other. 
Experiments with normal air-filled lungs or lungs 
rinsed with detergent show that the alveolar area de-
creases with increasing surface tension, suggesting an 
equilibrium exists in the lung between surface and tis-
sues forces [39].  In terms of the surface forces, from 
the LaPlace equation which relates the pressure (P) 
across a sphere such as the lung alveolus to the sphere’s 
radius, r (P = γ x 2/r, γ is the surface tension coeffi-
cient), as the radius decreases, if the surface tension 
was fixed, the transpulmonary pressure, P would have 
to increase [40, 41]. This unstable situation is avoided 
by lining the alveoli with a surface film which, as al-
veolar volume decreases allows reduction of the surface 
tension, γ, enabling the alveoli to reach stability. It is 
generally accepted that DSPC, and specifically that 
fraction which is composed of dipalmitoylphosphati-
dylcholine (DPPC), is primarily responsible for the 
surface tension lowering abilities of the pulmonary sur-
factant [42] and in fact is probably the only phosphol-
ipid capable of generating the very low surface tensions 
observed upon film compression [23]. This phosphol-
ipid displays a gel to liquid phase transition temperature 
of 41ºC, and thus exists in an ordered gel state at body 
temperature (37ºC) which has implications for its func-
tion as well as raising questions as to composition and 
spreadability in the alveolus [43]. This arrangement 
together with the uniformity associated with the satu-
rated palmitic acid moieties esterified to the glycerol 
backbone allows DPPC to pack closely at the air-water 
interface within the alveolus and, after reorganization 
into multi-layered surface pools [44, 45] to withstand 
the high compressive pressures during exhalation al-
lows the surfactant to achieve very low surface tensions 
in the alveolus. 
The other surfactant phospholipid of particular 
note is phosphatidylglycerol (PG). This phospholipid is 
present at undetectable to very low levels in cells and is 
predominantly involved in synthesis of cardiolipin (di-
phosphatidylglycerol) associated with the inner mito-
chondrial membrane [46]. During fetal lung develop-
ment, PG is maintained at low levels but, depending on 
the species, either immediately before or at birth PG 
levels in the surfactant rise until about 10% of the sur-
factant is accounted for by this phospholipid. Con-
versely the levels of phosphatidylinositol (PI) decline 
reflected the common intermediate in synthesis of PG 
and PI, CDP-diacylglycerol [47]. While the stimulus for 
this shift in synthesis of fetal lung from PI to PG near 
term is not clear, the elevated presence of PG in amni-
otic fluid has for some years been the basis of a diag-
nostic test to evaluate fetal lung maturity [48, 49]. It 
should be noted that recent assessments using such pa-
rameters as lamellar body counts (the intracellular stor-
age form of surfactant) [50] or ultrasound [51] may ul-
timately replace PG levels as diagnostic tools. The 
function of PG within the pulmonary surfactant is not 
clear. Administration of myoinositol, which induces a 
depletion of surfactant PG and a corresponding eleva-
tion of PI, does not seem to alter the efficiency of the 
6     Scott JE pulmonary surfactant [52, 53]. Nevertheless, recent evi-
dence suggests that the acidic phospholipids such as PG 
within the surfactant may interact with certain of the 
surfactant proteins (SP-B in particular) and may be re-
lated to selective adsorption of DSPC and reorganization 
of these phospholipids from the monomolecular film at 
the air-water interface of the alveolus [42, 43, 54]. 
Other minor phospholipids and neutral lipids ex-
ist in the pulmonary surfactant and while it is too early 
to dismiss their contributions as negligible, relatively 
few investigations into their functions have appeared. 
The reader is referred to recent reviews for more details 
[23, 55]. 
 
PROTEINS 
Four major proteins exist in the pulmonary sur-
factant. While they were recognized some years ago, it 
is only within the last few years that their functions 
have begun to be elucidated. Initially the proteins were 
thought to be derived in part from serum and there was 
considerable disagreement as to their number and func-
tion [56]. Today it is clear that several of these proteins 
are unique and all perform some basic function related 
to the processing, integration, reutilization, and proba-
bly other related functions of the surfactant. Surfactant 
proteins, termed SP-A, SP-B, SP-C and SP-D, have 
been localized to the surfactant obtained by bronchoal-
veolar lavage and all have been shown to perform some 
critical function ascribed to surfactant. Briefly, SP-A 
and SP-D are hydrophilic Ca
+2-dependent proteins, both 
of which appear to originate from the surfactant-
producing type II alveolar cell (see next section) and 
possibly the non-ciliated (Clara) cells of the bronchial 
epithelium [57]. SP-A is the most abundant of the sur-
factant proteins. It is highly conserved and has been 
identified in the lung of many species [58]. It displays 
collagenous and globular regions and is a member of a 
family of proteins termed collectins [59]. In lung lavage 
SP-A exists as a large oligomeric glycoprotein of about 
650 kDa in size [60] while the protein monomer has a 
molecular mass of 28-36kDa [61] depending on the 
degree of post-translational modification [61, 62]. The 
function of SP-A is still under debate and in fact it 
probably performs multiple functions, one being to act, 
along with SP-D, as broad spectrum alveolar opsonins 
[63]. However, its important nature in the surfactant is 
suggested by studies that demonstrated SP-A interacts 
with lipid mono- and bilayers [64], restores biophysical 
properties to oxidized surfactant [65] and mediates up-
take of phosphatidylcholine by type II alveolar cells 
[66]. Furthermore, potential interactions of SP-A with 
SP-B in formation of tubular myelin, the symmetrical 
phospholipid arrays intervening between the secreted 
lamellar bodies and the air-liquid monolayer has been 
demonstrated [67, 68], suggesting vital importance of 
these proteins to the surfactant. Ironically, recent stud-
ies with SP-A knockout mice, while showing some 
changes in surfactant properties, do not support a criti-
cal requirement in lung for SP-A as postnatal survival 
and pulmonary function were not altered [67, 69].  
SP-D, a collagenous 43 kDa glycoprotein secreted 
by type II alveolar cells [70], has also been identified in 
tracheal submucosal glands [57], the gastric antrum [71] 
and several other glands. SP-D consists of four homo-
trimeric units whose primary translation products are 
greatly enriched in the surfactant-producing type II al-
veolar cells [72]. A number of potential functions of SP-
D have been suggested [73]. Particularly noteworthy in 
this regard is the ability of SP-D to interact and partici-
pate in the clearance of microorganisms including in-
fluenza A by binding to oligosaccharides of hemagglu-
tinin [74, 75]. Within the surfactant, the contribution of 
this protein to function is not entirely clear. There has 
been some suggestion SP-D may have a particular af-
finity for phosphatidylinositol [76] if presented in the 
correct fashion, however, Taneva and colleagues (1997) 
could not demonstrate a head-group preference in sur-
face-balance studies and attributed SP-D interactions 
with phospholipid to hydrophobicity [77]. Nevertheless, 
mice with an SP-D null (SP-D -/-) genotype develop 
emphysema in the presence of elevated lung DSPC lev-
els [78], indicating that this surfactant protein does have 
some critical functions at the alveolar level. Finally a 
very important observation in SP-D (-/-) mice that in-
duced expression of rat SP-D corrects pulmonary sur-
factant abnormalities through a cell signaling mecha-
nism [79] suggests SP-D regulates surfactant metab-
olism in type II alveolar cells [80]. 
The remaining two surfactant proteins, SP-B and 
SP-C, are generally considered to be hydrophobic in 
nature and thus associate readily with the phospholipids 
of the surfactant. SP-B is expressed by both type II al-
veolar cells and the nonciliated bronchiolar epithelial 
Clara cells [81, 82]. Its function in the latter cells is not 
clear. In the lavage SP-B exists as a homodimer of 
about 18kDa [83]. Unlike the water soluble proteins, 
SP-B associates with phospholipid bilayers through 
amphipathic regions generated by the three dimensional 
α-helical association of polar and non-polar residues 
[84]. Evidence suggests that SP-B reacts to increasing 
surface tension by reorientation of its subunits into 
phase with each other [85] enabling reversible rapid 
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may also be involved in surfactant secretion through 
regulation of directionality related to apical and basal 
membranes of the type II cells as well as in formation 
of tubular myelin [86]. Hereditary deficiency of SP-B 
in human infants and in mice is associated with severe 
lethal respiratory distress [87, 88].  
SP-C exists as a very non-polar α-helical protein 
of approximately 4.2 kDa composed of a mixture of 
isoforms (see review by Johansson [89]). It appears to 
be the only surfactant protein exclusively expressed by 
lung tissue [82] and is the only surfactant protein de-
tected exclusively in the surfactant producing type II 
cells [90]. SP-C is altered posttranslationally by the 
addition of two palmitoyl groups to cysteines-5 and -6 
[89]. Changes in the degree of palmitoylation may be 
associated with some pathological conditions such as 
alveolar proteinosis [91]. In the surfactant, the amphi-
pathic nature of the α-helix may allow the protein to 
orient in a transmembrane way in bilayers of dipalmi-
toylphosphatidylcholine and dipalmitoylphosphatidyl-
glycerol [92]. However, in the surfactant the α-helical 
portion of the protein may occur such that the axis is 
almost parallel with the air-liquid interface [45, 93]. 
The palmitoylation phenomenon may influence the 
rapidity with which phospholipid within the subphase 
reservoir is recruited to the monolayer [94, 95]. How-
ever, the complex nature of the surfactant-subphase 
relationship at differing surface pressures may require 
or induce a variety of secondary structure conforma-
tions including extended β-sheets [85] despite evidence 
that SP-C is quite stable [96]. 
 
SOURCE OF THE SURFACTANT AND 
FUNCTIONAL CONSIDERATIONS 
Some 40 or more pulmonary cell types have been 
identified [14], making the lung by far the most hetero-
geneous of organs. However, at the level of the terminal 
respiratory units, the alveoli, a relatively simple cellular 
composition is present. The major lining cells which 
present an extremely large surface area to inhaled air 
and therefore any toxins are the type I alveolar cells 
[97]. This cell type covers some 90% of the gas ex-
change area and is very susceptible to injury [98]. Inter-
spersed among the type I cells are cuboidal type II al-
veolar cells. These cells are very active metabolically 
and, together with the non-ciliated bronchiolar (Clara) 
cells, are the source of the majority of the components 
of the surfactant [99, 100, 101]. Details of the biosyn-
thetic processes whereby surfactant phospholipids are 
formed and the hormonal control of this process is be-
yond the scope of the present discussion; the reader is 
referred to numerous reviews [19, 24, 100, 102, 103]. 
The major components of the surfactant, once formed 
within the type II cells, are incorporated into lamellar 
bodies which therefore represent the intracellular stor-
age form of the surfactant [104]. These osmiophilic 
bodies are easily identifiable in type II cells and the 
complex regulatory mechanisms whereby they are se-
creted are in part, worked out [55, 106].  In addition to 
synthesis and secretion, over the last decade it has be-
come apparent that major quantities of the pulmonary 
surfactant, after being released into the hypophase and 
sorted to the monomolecular phospholipid layer which 
lies at the air-liquid interface, are reutilized [107, 108, 
109] (Figure 2). In neonates, as much as 90% of the 
surfactant is reutilized [110]. The processing of the ex-
tracellular material within the hypophase in the alveolus 
can be divided into several different stages reflecting 
the biophysical characteristics of the surfactant. Separa-
tion of the various forms by centrifugation [111, 112] 
has shown a spectrum of attributes measurable by den-
sity, surface activity and infrared signatures [113, 114]. 
As these fractions exist extracellularly, exposure to 
smoke or other environmental pollutants may directly 
alter the processing at various stages of this extracellu-
lar material [115, 116]. Furthermore changes in proc-
essing and reuptake may be associated with some dis-
eases such as pulmonary alveolar proteinosis [59]. 
DPPC, as the primary phospholipid of the surfac-
tant, is generally considered to display the surface ten-
sion characteristics required to withstand the high sur-
face pressures that occur during the exhalation phase of 
the respiratory cycle [33]. However due to the high gel 
transition temperature of DPPC (41ºC), a film of this 
material would exist in a solid gel state at body tem-
perature. Thus, for the film to be spreadable at 37ºC, 
addition of cholesterol or other unsaturated phospholip-
ids is necessary [28]. Within the alveolus, the lining 
surfactant has traditionally been considered to exist as a 
thin continuous layer. The application of modern imag-
ing techniques such as cryo-scanning or transmission 
electron microscopy have supported this view and 
shown a thin continuous layer in the alveolus [117]. In 
this model, interaction of phospholipids and proteins 
within the alveolus accounted for the low surface ten-
sion and through a process of “squeeze-out” the mono-
molecular film at the surface air-liquid layer was be-
lieved to be enriched in DPPC [118] allowing the 
generation of surface tension values observed for the 
lung surfactant. However, observations using the most 
recently developed instrumentation such as scanning 
8     Scott JE force or atomic force microscopy which allow visuali-
zation at the molecular level provide strong evidence 
that this theory is inaccurate [45, 105, 119, 120]. 
Rather, recent views suggest the existence of multiple 
layered regions in a non-homogeneous surface surfac-
tant [21]. The multi-layered regions unfold successively 
during inhalation and collapse into the layered form 
again upon expiration. These multilayers have been 
visualized [105]. The hydrophobic surfactant proteins B 
and C in particular may be intimately involved in orga-
nizing this process [45, 120] and appear to be segre-
gated in a liquid expanded compared to a condensed 
phase [121, 122]. Thus surfactant metabolism involves 
not only the steps of intracellular synthesis and secre-
tion, but multiphase complex transitions within the hy-
pophase between various compartments. This allows 
many potential sites for interaction or interference with 
the surface tension-generating characteristics of the 
surfactant which may ultimate be reflected in stability 
of the alveolus. 
 
TOBACCO SMOKE AND LUNG SURFACTANT 
From the foregoing brief description of the pul-
monary surfactant system, it is clear that the surfactant 
Figure 2: Scheme showing the route for de novo surfactant (DPPC) synthesis, secretion as lamellar bodies, 
transposition to tubular myelin and reutilization of components in lung type II cells. Phospholipids are repre-
sented by filled circles (polar head group) with fatty acid chains projecting into the air away from the polar
hypophase. Potential examples of single sites of surfactant protein function (SP-A, SP-B, SP-C and SP-D) are 
shown; multiple functions and sites are likely. New concepts concerning the surface reservoir are indicated by
the multiple phospholipid layers at the air-liquid interface [45, 105]. Note the extensive extracellular process-
ing of the surfactant as it is secreted at the apical surface of the type II cell, the air-hypophase interface and 
reutilization. 
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plex face, both in terms of composition and function, to 
any materials reaching the respiratory tissues. At the 
level of the air exchange tissue, the pulmonary surfac-
tant presents the first interface encountered by inhaled 
smoke, whether from tobacco, marijuana or any other 
inhaled aerosolized material, for example fungal spores, 
mites or other allergens. Tobacco use and the potential 
for exposure to environmental tobacco smoke (ETS) 
has become an extremely important issue over the last 
several decades as it has become apparent that smoking 
carries with it a major and also preventable risk for the 
development of lung cancer. Lung cancer accounts for 
about 30% of all cancer deaths in men and 20% of all 
cancer deaths in women [10]. In the United States, lung 
cancer accounts for 20% of all economic costs related 
to cancer treatments. This massive burden on the health 
care system is largely due to the continuing exposure to 
cancer-causing agents in tobacco smoke. Indeed some 
80% of lung cancer deaths can be attributed to smoking 
[9, 123, 124]. The issue of susceptibility to induction of 
smoking-related lung cancer is a complex problem and 
beyond the scope of the present review. The reader is 
referred to recent compilations for further analysis and 
details [124, 125]. In those that do not smoke many 
factors may play a role in development of lung cancer, 
not the least of which is ETS although the risks are 
much lower than in smokers and have proven difficult 
to estimate [126, 127]. 
Tobacco smoke contains between 2,000 and 
4,000 agents [128] that may exert toxic effects at differ-
ent levels within the respiratory system and indeed dis-
tribute themselves, depending on their physical charac-
teristics, at varying levels down the bronchial tree [129, 
130]. These compounds consist of a wide range of both 
organics and inorganics. In addition, volatile organic 
compounds (VOC’s) in particular, some of which are 
naturally occurring in the tobacco plant while others 
such as asbestos and glass fibers occur as additives dur-
ing the manufacturing process [131] are present. 
Whether from direct inhalation of tobacco smoke or 
secondhand smoke (ETS), as a first line of defense, the 
pulmonary surfactant is exposed primarily to inhaled 
gas-phase materials from tobacco or marijuana smoke 
and, to a lesser degree depending on the route, the par-
ticulates within the smoke as they are distributed within 
the airways. Thus, the cellular reaction to smoke expo-
sure will depend to a great degree on the tissue level, 
the exposure material, either particulate or gas phase, 
and the effects of a complex mix of toxins on cellular 
metabolism. Since this review is focused on the pulmo-
nary surfactant, we will assume here that components 
of the smoking process reach the terminal respiratory 
units and indeed this would seem to be the case, par-
ticularly for the gas phase constituents although particu-
late deposition in the airways, including the alveolar 
ducts and the entrance to alveoli, probably occurs [132]. 
The entire deposition process is very complex with the 
airways accumulating very specific sizes and types of 
particles [133, 134]. Some of the smallest particles may 
even penetrate the mucosal epithelium, entering the 
pulmonary interstitium [135]. Thus, the effect on the 
pulmonary surfactant and indeed the entire lung may 
vary widely depending on the level and the type of con-
taminant. In this regard the actual physical characteris-
tics of the surfactant, disregarding the contaminants’ 
effects on synthesis and/or secretion, may be altered by 
many factors including subphase calcium [136], free 
oxygen radicals [137] and plasma proteins [138]. Con-
sequently, the components of smoke may be expected 
to alter the surface tension lowering capabilities of 
pulmonary surfactant. 
Studies of the direct effects of tobacco smoke on 
pulmonary surfactant have been few. Several older 
studies [139, 140] suggest smoke may interact directly 
with surfactant and the ability to generate low surface 
tension may be impaired [140, 141]. Higenbottam 
(1989) used a Wilhelmy balance to investigate if sur-
face tension was altered in the presence of complete or 
filtered smoke [142]. While the smoke gas phase did 
not appear to change the hysteresis of the surface ten-
sion-area curve, whole smoke was surface-active, sug-
gesting the particulates in smoke may have a detergent-
like action. The majority of other studies have com-
pared the characteristics of lung function or lung lavage 
in smokers and non-smokers. Tobacco smoke exerts a 
wide spectrum of biological effects on the lung and 
cells of the lung airways, including DNA damage [143], 
DNA single strand breaks in cultured human lung cells 
[144], bronchoconstriction associated with increased 
thromboxane levels [145], development of emphysema 
[146] and COPD [147]. Smoke may also stimulate the 
proliferation of lung cells through a ligand-epidermal 
growth factor receptor mechanism activated by tumor 
necrosis factor converting enzyme and oxygen radicals 
[148]. It is therefore not surprising that, at the level of 
the distal airways and alveoli, cigarette smoke alters the 
milieu of the air exchange tissues and distal airways. 
Smoking appears to reduce the overall recovery 
by endobronchial lavage of surface active material and 
phosphatidylcholine in particular [149], although more 
recent reports suggest this change may not be as great 
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tradictory finding suggests an initial rise in alveolar 
surfactant levels may occur [153, 154] which the au-
thors attribute to the short-term moderate-smoker char-
acteristics of the population sampled. While several 
studies have been unable to detect alterations in the 
general phospholipid profile in the lavage fluid, the 
complexity of the lavage material dictates that such 
findings be taken in a critical light. Zetterberg and col-
leagues (1995) detected a higher fraction of palmitoyl-
myristoyl phosphatidylcholine in smokers [155] but did 
not find any changes in other disaturated phospholipids, 
which may suggest that the surface activity in the lung 
is within normal ranges since it is predominantly disatu-
rated phosphatidylcholine on which this characteristic 
relies. On the other hand, Subramaniam and colleagues 
(1995), in an experimental model of chronic cigarette 
smoke exposure in rats, did detect a reduction in bron-
choalveolar lavage DSPC levels but not tissue DSPC, 
suggesting smoke exposure alters surfactant secretion 
from type II alveolar cells [156]. In one of the few stud-
ies of surface tension characteristics, these authors also 
observed a major increase in surface film compressibil-
ity, probably related to the reduced DSPC. Taken to-
gether, these results suggest that at least chronic smoke 
exposure reduces pulmonary surfactant phospholipid 
levels. 
Some changes have also been documented in 
other phospholipids. Specifically increases in phos-
phatidylethanolamine and sphingomyelin levels have 
been noted [153, 154] possibly indicating cellular dam-
age as these phospholipids are more associated with cell 
membranes than the pulmonary surfactant. Hughes and 
Haslam (1990) also observed significant reductions in 
the levels of lung lining fluid cholesterol and the cho-
lesterol:phospholipid ratio in smokers which may in 
part explain surface tension changes observed in the 
chronic smoke exposure model [156] as this neutral 
lipid (cholesterol) may have an important role in fluid-
ity [157]. The possibility also exists that smoking alters 
pulmonary repair processes as smoke extract appears to 
inhibit TGF-β and fibronectin release at the level of the 
bronchial epithelium and may conceivably have similar 
effects within the distal air spaces [158]. Obviously 
many factors are in play in interpreting smoking effects 
on surfactant phospholipids and it is too simplistic to 
expect a single effect or causative factor. Furthermore, 
it is important to bear in mind the complex nature of the 
surfactant components and their interactions. In this 
regard it is important that evidence is beginning to ap-
pear that smoking may alter the content, activity or 
properties of the surfactant proteins important to the 
cycling and generation of surface tension [159]. Effects 
on the proteins will be discussed later. 
In addition to elevated numbers of alveolar 
macrophages [160], smokers show a severalfold in-
crease in alveolar cells in lavage fluid and an increase 
in the numbers of cells expressing MHC molecules, but 
an overall underexpression of MHC and cell adhesion 
factor (LFA-1) molecules in these cells of the respira-
tory tract [154]. These authors also noted an overload-
ing of alveolar macrophages with black inclusions 
which had been observed previously [161, 162] and 
may be related to reduced surfactant levels [149] as 
macrophages phagocytose spent surfactant [163]. In 
this regard it is interesting to note that surfactant has 
recently been shown to improve mucociliary clearance 
in a model of acute induced bronchitis [164]. These 
observations would appear to support the idea that a 
thin surfactant layer intervenes along the bronchial epi-
thelium between the mucus gel layer and the periciliary 
fluid surrounding the bronchial epithelial cilia [165, 
166, 167]. In fact in a model of acute bronchitis induced 
by SO2 gas exposure, surfactant may improve muco-
ciliary clearance from the bronchial tree [164]. How-
ever in smokers, this mucus-surfactant layer appears to 
be cleared much less rapidly compared to non-smokers 
[168]. This may be due to reduced ciliary activity and 
clearance rates in smokers [169, 170]. Alternatively, or 
probably in addition to this mechanism, tobacco smoke 
may induce overproduction of mucin through activation 
of an epidermal growth factor receptor mechanism 
[171]. In any case, whether due to hypersecretion of 
mucus or smoking-induced reduction of clearance rates 
particularly in the larger airways [172], the ultimate 
effect is to increase mucus levels, possibly through the 
transcription factor NF-κB [173], thereby altering the 
pulmonary airway environment and increasing suscep-
tibility to diseases such as asthma, cystic fibrosis or 
bronchitis. While this mechanism may explain elevated 
mucus levels, the increased load induces an elevation in 
ciliary beat frequency until uncoupling occurs [174]. 
What overall effect this has on the intervening surfac-
tant layer at this level of the bronchial tree is not clear 
as smoke-induced effects have not been examined and 
the interactions of surfactant and mucus await further 
study. 
At the molecular level, little is known about how 
smoke components interact with the surfactant either in 
the alveolus or at higher levels in the bronchial tree. 
Subramaniam and colleagues (1996) observed elevated 
levels of albumin in rat bronchoalveolar lavage follow-
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implications for the ability of surfactant to generate low 
surface tension as blood proteins such as albumin and 
fibrinogen are known to be detrimental to generation 
of low tension [176]. In addition cigarette smoke con-
tains many compounds that may generate free radicals. 
Generally two populations of free radicals are present. 
The first is located in the tar or particulate phase, is 
relatively stable and reacts with DNA [177]. In contrast, 
the free radicals within the gas phase are less stable and 
much more reactive than those of the tar phase. While 
these compounds undoubtedly are implicated in such 
diseases as lung cancer and emphysema [177], some 
evidence has appeared that they induce injury to the 
surfactant-producing type II cells in the alveolus. 
Work by Lannan and colleagues (1994) suggests that 
the oxidant-antioxidant balance in the airspaces is im-
portant for alveolar cell function as both whole and 
vapour phase cigarette smoke were observed to de-
crease cell attachment and proliferation [178] while 
reactive oxygen species (ROS) were elevated [179]. 
Cigarette smoke extract also potentially induces necro-
sis and apoptosis, in a concentration-dependent fashion 
in A549 cells [180] and bronchiolar epithelial cells 
[181]. However it should be noted that A549 lung 
tumor cells display distinct differences from typical 
lung type II alveolar cells [182]. 
In a limited series of experiments, freshly isolated 
rat alveolar type II cells appeared to undergo cell lysis 
after exposure to tobacco smoke [178]. The importance 
of the surfactant in maintaining a biologically advanta-
geous environment has clear implications for surface 
tension levels in the alveolus. Ozone exposure reduces 
the ability of the surfactant to maintain tube patency in 
a capillary surfactometer [183], reduces lung compli-
ance and alters phospholipid levels [184]. Further, re-
cent evidence of oxidative damage specifically to bron-
chiolar epithelial cells and type II alveolar cells 
suggests smoke exposure induces DNA damage and 
lipid peroxidation [185]. This may have implications 
for surfactant protein function as evidence has recently 
appeared that SP-A and SP-D contribute significantly to 
protection of the lung from oxidative stresses associated 
with exposure to air pollutants, oxygen or other agents 
[186]. 
In addition to the effects described above, some 
preliminary studies suggest cigarette smoke or smoke 
by-products affect the proteins of the pulmonary surfac-
tant. Bronchoalveolar lavage samples from smokers and 
non-smokers showed reduced levels of SP-A and SP-D, 
standardized to lavage phospholipid levels [159] by 
ELISA and using human monoclonal antibodies to each 
protein. In an animal model, smoke exposure dramati-
cally reduced the levels of both SP-A and SP-B in 
bronchoalveolar lavage but neither tissue protein nor 
lung RNA levels were altered [175]. On the other hand 
serum levels of SP-A appear to be increased in smokers 
[187, 188]. It is not clear what implication these obser-
vations have for the ability of alveolar surfactant to 
generate low surface tension but may reflect changes in 
the complex cycling of surfactant in the hypophase as 
well as changes in synthetic and/or secretion rates. 
Many other constituents of tobacco smoke may 
potentially alter or harm the pulmonary surfactant or 
type II cells. Of particular note, nitrogen dioxide, an-
other constituent of tobacco smoke and a major envi-
ronmental urban pollutant [189], has been examined for 
its ability to alter pulmonary surfactant synthesis or 
secretion. The effects of this agent on these processes 
will be discussed in the following section. 
 
SMOKE EFFECTS ON SYNTHESIS AND 
SECRETION OF LUNG SURFACTANT 
It is generally accepted that surfactant deficiency, 
due to the immature nature of the surfactant-producing 
type II alveolar cells, is the main causative factor in the 
development of respiratory distress in prematurely de-
livered infants [190]. However, evidence is beginning 
to appear that components of the pulmonary surfactant, 
including the proteins, may be altered in various other 
disease states including such diseases as cystic fibrosis 
[191], asthma [192, 193, 194], allergic alveolitis [195] 
and chronic obstructive pulmonary disease (COPD) 
[196]. The associated changes may be primary or sec-
ondary and probably reflect alteration of the synthesis, 
secretion or reuptake of surfactant. Indeed the well es-
tablished link between COPD and smoking suggests 
that surfactant may be a target for tobacco-induced 
pulmonary diseases [197]. Considering that smoke, its 
various components and possibly particulate matter 
reach the alveolar ducts and alveoli themselves, it might 
be expected that it would affect the intracellular syn-
thetic rate, release, and probably the reuptake of the 
surfactant. Surprisingly little information is available 
concerning the effects of smoke on these processes.  
As noted above there is good evidence that smok-
ing is associated with reduced surfactant phospholipids 
in the bronchoalveolar lavage [149]. This may reflect 
the ability of smoke to reduce the levels of DSPC secre-
tion, as observed in a rat model [156]. Similarly using 
an in vitro system of adult rat type II alveolar cells, 
Wirtz and Schmidt (1996) observed that cigarette 
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of radiolabelled phosphatidylcholine [198]. This may 
involve the intracellular assembly and delivery of the 
surfactant to the cell membrane as smoke exposure al-
ters the levels, although it causes an increase, of a 
phospholipid binding protein, annexin I in both type II 
alveolar cells and lavage fluid [199]. Such an effect 
may be explainable as a compensatory mechanism 
since no measures of annexin binding capacity were 
done to define the activity of the protein after smoke 
exposure. On the other hand, smoke generated by burn-
ing polyurethane foam did alter tissue DSPC levels and 
reduced enzymatic activity of phospholipase A2, sug-
gesting the pulmonary effects may vary according to 
the type and composition of the inhaled smoke [115]. 
Furthermore individual smoke constitutents such as 
NO2 may have different effects as this compound ap-
pears to increase both the incorporation of precursors 
into surfactant phospholipids through enzyme activa-
tion, particularly CTP:cholinephosphate cytidylyltrans-
ferase, which regulates phosphatidylcholine synthesis 
[200, 201] and release of phosphatidylcholine in iso-
lated rabbit type II cells [200, 202]. In fact cellular 
damage may be connected to the release as LDH levels 
were correspondingly increased. Thus some evidence 
exists that smoke products have the ability to markedly 
alter intracellular synthetic and secretory rates, proba-
bly through effects on enzymatic conversion or trans-
port of surfactant components within type II cells. 
However it is difficult to generalize as to the potential 
Figure 3: Examples of some potential sites where smoke exposure may alter surfactant metabolism. 1: Par-
ticulates may have a direct detergent-like effect on the surface monolayer. 2: Lipid peroxidation induced by
smoke exposure. 3: Transport of surfactant-specific phospholipid and altered secretion of lamellar bodies. 4
and 5: Reduced levels of SP-A and SP-D may affect hypophase processing directly or indirectly or alter SP-D 
regulation of DPPC synthesis. 6: Nicotine may alter receptor expression in fetal lung. 
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thesis and secretion. 
 
SMOKE EFFECTS ON LUNG DEVELOPMENT 
Despite early observations that smoke exposure 
during pregnancy actually hastens pulmonary matura-
tion [203, 204] which was ascribed to “adverse preg-
nancy conditions” [203], many recent studies have 
rather conclusively shown that smoking during preg-
nancy comes at a high cost. Prenatal smoke exposure 
has been shown to be associated with neonatal mortality 
[205], low birth weight/growth retardation [206] and an 
increase in the rate of spontaneous abortions [207]. In 
relation to the pulmonary system, impairment of infant 
breathing [208, 209, 210, 211] and breathing control 
[212], retardation of lung growth [213], reduced flow 
rates in infants of smoking mothers [214, 215] particu-
larly in children who develop asthma [215] as well as 
increased airway responsiveness [216, 217], a hallmark 
of asthma have been reported. Furthermore compres-
sion of the fetal lungs, reduction of fetal breathing 
movements, hypoxia [218, 219] or placental insuffi-
ciency are among many factors that can be directly re-
sponsible for respiratory compromise in later life [211]. 
Maternal smoking and fetal exposure during pregnancy 
may be significant components of many of these causa-
tive factors which may persist, even without early post-
natal smoke exposure [220, 221] and induce pulmonary 
changes. Pulmonary cell apoptosis, hyperplastic bron-
chial smooth muscle and mesenchymal disorganization 
were reported in rat pup lungs exposed in utero to 
smoke [222]. In fact, some evidence suggests exposure 
to tobacco smoke components during pregnancy may 
play a much greater role in altered lung function than 
postnatal or childhood exposure [223]. These pulmo-
nary changes appear to occur early in pregnancy as res-
piratory function in premature infants of smoking 
mothers is significantly reduced compared to premature 
infants of nonsmokers [224], indicating insult to the 
developing respiratory tissues does not occur only dur-
ing the late stages of pregnancy. Such a stress-induced 
mechanism may indeed explain some of the observa-
tions as a glucocorticoid effect on pulmonary matura-
tion may be instrumental in induction and regulation of 
lung development and several components of the pul-
monary surfactant [55]. The ultimate effect of smoke 
exposure in utero and the postnatal period on the pul-
monary surfactant is, however, not clear. In rat pups 
from smoke-exposed mothers and following postnatal 
sidestream exposure changes in dynamic compliance, 
reactivity to methacholine [225], and biochemical 
changes in total lavage phospholipids and decreased 
lavage SP-A levels were detected [226]. However in the 
latter study, these changes were not reflected in corre-
sponding changes of the biophysical properties of the 
lavage surfactant as measured on a pulsating bubble 
surfactometer. 
While many agents in smoke may be detrimental 
to fetal development, some evidence supports a direct 
effect of nicotine on lung development suggesting that 
nicotine is capable of altering lung maturation. Nicotine 
crosses the human placenta with only minimal biotrans-
formation to cotinine [227]. It accumulates in fetal 
blood, maternal milk and amniotic fluid [228] despite 
increased nicotine clearance during pregnancy [229] 
and may result in the fetus being exposed to even 
higher levels than those of the smoking mother [230]. 
This material appears to accumulate in several fetal 
tissues including the respiratory tract and urinary blad-
der [231]. However, what exactly the nicotine does at 
the level of the lung is not clear. Maritz and colleagues, 
in several morphological studies appear to have demon-
strated that nicotine exposure during pregnancy de-
creased the ratio of type I:type II cells in the neonatal 
lung as well as increasing the lamellar body content of 
the latter cell type [232]. As the type II cells are the 
precursors to the type I cells in injured lung [233] and 
both probably share a common progenitor cell type in 
the fetal lung [234], such a shift suggests a major effect 
on differentiation of the alveolar epithelium. In addition 
the accumulation of lamellar bodies further suggests 
that secretion of surfactant may be inhibited following 
nicotine exposure although this may be related to an 
overall alteration in glucose metabolism observed in 
fetuses exposed to this drug in utero [235]. Changes 
have also been described in connective tissue compo-
nents of lung and lung airways associated with nicotine 
treatment during pregnancy. At the alveolar level, 
Maritz and Woolward (1992) observed a reduction in 
elastic tissue content and suggested this may potentially 
make infants exposed to nicotine more susceptible to 
emphysema [236]. Quantification of nicotine effects on 
developing fetal rat lung [237] suggests an overall re-
tardation of growth and maturation, and an increase in a 
destructive index previously associated with lung em-
physema of adult smokers [238].  Nicotine also induces 
an up-regulation of α7-nicotinic acetylcholine receptors 
(nAChR’s) in lung, an increase in collagen and elastin 
deposition in the airways as well as an increase in al-
veolar type II cell numbers in fetal monkey lung [239, 
240]. The authors interpret these findings, in light of the 
degree of lung hypoplasia detected, to mean that nico-
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in the fetus. However as they note, multiple binding 
sites for nicotine in developing lung, including the neu-
roendocrine cells, probably signifies a complex, multi-
dimensional effect on the lung including such complex 
mechanisms as regulation of dichotomous branching, 
connection tissue interactions and muscle induction 
[239]. Indeed the neuroendocrine cells which pheno-
typically resemble small cell lung carcinomas appear 
also to be binding sites for the tobacco-specific car-
cinogen NNK through a MAP kinase/c-myc pathway 
via nAChR’s and may provide several alternative routes 
whereby lung development may be altered through a 
paracrine serotonin pathway [241, 242]. 
While these studies overwhelming support the 
detrimental role for tobacco smoke exposure on prena-
tal and postnatal lung development and the overall well-
being of the fetus, paradoxical evidence alluded to at 
the first of this section suggests that smoke-exposed 
fetuses display a state of advanced lung maturity [203, 
204]. Such an effect is supported by evidential meas-
ures of amniotic fluid Lecithin/Sphingomyelin (L/S) 
ratio and saturated phosphatidylcholine levels [243] 
which would suggest an acceleration of maturation by 
approximately one week. These same investigators ob-
served an elevation of amniotic fluid cortisol, providing 
strong support for the contention that the smoke-
induced effect is secondary to fetal stress and hypoxia 
[244, 245], and that glucocorticoids play an important 
role in stimulation of lung maturation [103]. Neverthe-
less recent evidence suggests a direct nicotine effect as 
in vitro exposure of embryonic lung explants induced 
morphogenetic branching and enhanced expression of 
surfactant proteins A and C and the Clara cell-specific 
marker CC10 [246]. This action may be related to the 
presence of the nACHr’s in lung and it is relevant to 
note again that these receptors appear to be present in 
airway epithelial cells as well as the pulmonary neuro-
endocrine cells and type II cells [239]. Nevertheless it 
has not been determined what role activation of these 
receptors may play in the latter cell type and if it relates 
in any way to the regulation of surfactant synthesis and 
secretion.  
 
CONCLUSIONS 
Tobacco smoking, primarily through the use of 
cigarettes, was at one time a pervasive and accepted 
social habit. While use has declined to some extent in 
selected areas and the “acceptedness” of smoking, par-
ticularly in indoor environments, has similarly declined, 
exposure to tobacco smoke still remains a major health 
risk particularly in developing countries [247]. Inhala-
tion of tobacco smoke has major effects on the lung, 
one being the induction of lung cancer. Subtler effects 
on the lung and the pulmonary surfactant are probable 
as the extant research literature supports the detrimental 
nature of smoke on many lung processes. The pulmo-
nary surfactant in particular which forms the first line 
of defense against inhaled materials may be adversely 
affected but evidence of such an effect has not been 
examined in great detail. Additional research in this 
area is clearly required. Part of the reason for this lack 
is likely the complex nature of the smoke generated by 
cigarettes which as a result makes it difficult to select 
likely candidates in this complex cocktail of volatile 
and particulate matter for study. Nonetheless, many of 
the major components such as nicotine and nitrogen 
dioxide have documented effects, although many de-
tails still remain to be elucidated. 
With regard to the developing fetus and fetal lung 
where the critical nature of the developmental process 
is underscored by the mortality levels due to respiratory 
distress, little question remains that smoking during 
pregnancy is detrimental. Altered fetal intracellular 
enzyme levels, receptor binding proteins and surfactant 
proteins are among some of the initial findings. Fur-
thermore these changes are reflected in altered lung 
mechanics in the newborn which may extend into later 
periods of development and may compromise normal 
expansion and compliance during childhood. Clearly 
more research and application of markedly more so-
phisticated techniques as well as development of in 
vitro models will be necessary to establish smoke ef-
fects on lung function. This will enable characterization 
of the mechanisms by which agents in smoke poten-
tially alter lung maturation, the developing respiratory 
tissues, and particularly the pulmonary surfactant. 
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